Advertisement
Skip to Content

iShares Biotechnology ETF IBB ETF Analysis

| Quantitative rating as of | See iShares Investment Hub

Morningstar’s Analysis IBB

Will IBB outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

Summary

|

Increased confidence in iShares Biotechnology ETF's prospects relative to its Morningstar Category peers leads to an upgrade in this strategy's Morningstar Quantitative Rating to Neutral from Negative. The portfolio maintains a sizable cost advantage over competitors, priced within the cheapest fee quintile among peers.

Unlock our full analysis with Morningstar Investor